#1 is my main beef. Things happen and they're out of the control of the company. But there is no reason to not issue clear guidance on what's going to happen going forward.
I think all 4 of your points WILL happen between now and years end fabius...but for sure we'll be seeing 40mg FocalinXR bioequivalence progress clarity in IPCI's pending financials IMO...the only 1 of the 4 points that continues to be so tough to gauge is if/when the FDA finally releases the 1st of IPCI's 2 over +5 year old ANDA's still stuck in the FDA's ANDA backlog:)